Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:46:46.965Z.
Calculation as of: 2026-10-06T15:46:46.965Z.
Quote observation: 2026-10-06T15:44:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cd3ead22764b77a02cf3e742533c366d0c9255af04c84535b20f2b2666bee2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$77.80M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$68.84M
EV/EBIT Ratio
N/A
TTM Avg
25.28x
3Y Avg
28.49x
5Y Avg
157.43x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $74.22M | N/A | N/A | N/A | N/A |
| Outset Medical, Inc. (OM)vs › | $76.47M | N/A | N/A | N/A | N/A |
| Hyperfine, Inc. (HYPR)vs › | $76.59M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.80M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $70.25M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $69.26M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $68.84M | N/A | 25.28x | 28.49x | 157.43x |
| Pulmonx Corporation (LUNG)vs › | $80.04M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $80.37M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
